Orthocoronavirinae infectious disease

Related records

Broader conditions (9)

• Coronaviridae infectious disease
• Disease
• Disease by etiologic mechanism
• Disease of primarily extrinsic mechanism
• Human disease
• Infectious disease
• Nidovirales infectious disease
• Primary viral infectious disease
• Viral infectious disease

Narrower conditions (3)

• COVID-19
• Middle East respiratory syndrome
• Severe acute respiratory syndrome

Trials (1,130)

• "COVID-19 and Diabetes Outcomes"
• A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
• A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)
• A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
• A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection
• A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit
• A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device
• A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
• A Longitudinal Study of COVID-19 Sequelae and Immunity
• A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)
• A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
• A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
• A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
• A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
• A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
• A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
• A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
• A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)
• A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
• A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Approved drugs (2)

• Lexgenleucel-T
• Remdesivir

Drugs in development (34)

• ABC-294640 Phase 2
• Aloxistatin
• Azithromycin Phase 3
• Azithromycin monohydrate Phase 3
• Azoximer bromide Phase 2
• Bevacizumab Phase 2
• Budesonide Phase 3
• Colchicine Phase 2
• Conestat alfa Phase 2
• Escin Phase 2
• Favipiravir Phase 3
• Human immunoglobulin G Phase 3
• Hydroxychloroquine Phase 3
• Hydroxychloroquine sulfate Phase 3
• Interferon Phase 1
• Interferon alfa Phase 1
• Interferon alfa-2B Phase 1
• Ketamine Phase 2
• Lopinavir Phase 3
• Mefloquine Phase 2

Other linked drugs (4)

• Almitrine
• Almitrine mesylate
• Atorvastatin
• Ezetimibe